What if we could prevent treatable disease before it developed?

That’s precisely our goal.

The International Consortium on Newborn Sequencing (ICoNS) unites global expert genomic scientists, clinicians, and stakeholders to define the future of genomic newborn screening (gNBS) and preventative health. We provide the trusted, collegial environment where thought leaders collaborate to address the field's most challenging topics. Our core focus is driven by our mission: to inform the clinical and public health research and implementation of genomic screening in newborns through the harmonization and aggregation of scientific evidence and resources. ICoNS subcommittee activities ensure that the integration of newborn sequencing is built upon rigorous, harmonized, and globally accepted standards for decision-making worldwide.

JOIN ICoNS

News & Research

JANUARY 7, 2026

Engage with the world's leading experts as they collegially dissect and resolve the most complex, ambiguous challenging cases submitted from the field during ICoNS' real-time monthly consortium calls.

OCT 8, 2025

Professor Dame Sue Hill, CSO of England, at ICoNS’25 in London

JANUARY 2026

Operationalizing the Wilson-Jungner principles for the genomics era

Activities

To achieve our objective of advancing the scientific and clinical knowledge of genomics in newborns, our subcommittees focus on the harmonization of evidence and resources. We are dedicated to nurturing the next generation of leaders who will implement genomic screening on a public health scale—alleviating human suffering by serving at the intersection of science and clinical care on a global level.

Gene List

Economics

Data Sharing

Analysis

Policy & Ethics

ICoNS'X

Annual Convening of Global Thought-Leaders and Stakeholders in Newborn Sequencing. Representatives Across the Entire Healthcare Ecosystem From Over 50 Countries.

Clinicians • Researchers • Policy Makers • Technology • Therapeutics • Advocacy • Diagnostics • Ethics • Hospital Systems • Laboratories

Results from genome sequencing at birth can detect risk for treatable disease before symptoms even start, allowing clinicians to manage or prevent the onset of disease.
Newborn sequencing is far more comprehensive than current newborn screening and can be referred to throughout the lifespan, allowing individuals to make proactive healthcare decisions that may improve their future and the health of their family.
Integrating newborn sequencing into everyday medicine will require careful consideration for healthcare systems and for families, including strategies that address privacy issues, cost, equity, clinician education, and more.